- Home
- ZVRA
as 03-25-2025 12:39pm EST
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | CELEBRATION |
| Market Cap: | 433.5M | IPO Year: | 2015 |
| Target Price: | $22.29 | AVG Volume (30 days): | 531.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.20 - $9.76 | Next Earning Date: | 03-11-2025 |
| Revenue: | $23,612,000 | Revenue Growth: | -14.02% |
| Revenue Growth (this year): | 281.1% | Revenue Growth (next year): | 97.98% |
Stock Insider Trading Activity of Zevra Therapeutics Inc. (ZVRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bode John B | ZVRA | Director | Mar 19 '25 | Buy | $7.96 | 10,000 | $79,624.00 | 40,000 | |
| Sangiovanni Timothy J. | ZVRA | SVP, Finance & Corp Controller | Feb 13 '25 | Sell | $7.86 | 3,000 | $23,587.80 | 16,341 | |
| McFarlane Neil F. | ZVRA | President and CEO | Feb 13 '25 | Sell | $7.95 | 91,817 | $727,389.76 | 222,060 | |
| Clifton R. LaDuane | ZVRA | CFO & Treasurer | Feb 13 '25 | Sell | $7.86 | 11,000 | $86,471.00 | 51,361 | |
| Schafer Joshua | ZVRA | CCO & EVP, Bus. Development | Feb 13 '25 | Sell | $7.86 | 10,500 | $82,526.85 | 29,486 |
Latest Zevra Therapeutics Inc. News
ZVRA Breaking Stock News: Dive into ZVRA Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Zevra Therapeutics Independent Director Acquires 33% More Stock
Simply Wall St.
12 days ago
Zevra Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
MT Newswires
13 days ago
Sector Update: Health Care Stocks Decline Wednesday Afternoon
Thomson Reuters StreetEvents
13 days ago
Q4 2024 Zevra Therapeutics Inc Earnings Call
GuruFocus.com
14 days ago
Zevra Therapeutics Inc (ZVRA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ...
Zacks
14 days ago
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates
Associated Press Finance
14 days ago
Zevra Therapeutics: Q4 Earnings Snapshot
MT Newswires
14 days ago
Zevra Therapeutics Q4 Net Loss Widens, Revenue Decreases; Shares Fall After Hours
Compare ZVRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZVRA Zevra Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.